BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced it has been recognized with the “Therapeutics Platform Of The Year” award in the third annual BioTech Breakthrough Awards program.
The program was conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. The award recognizes BPGbio’s success leveraging their NAi Interrogative Biology Platform to develop late-stage therapeutics and diagnostics for some of the most challenging diseases.
“We are honored that BPGbio has won the Therapeutics Platform of the Year from BioTech Breakthrough, a massive achievement for our employees and research partners. This recognition highlights the robust late-stage clinical pipeline that is leading the Biology-First AI drug discovery industry in putting AI developed therapeutics into the clinic,” said Niven R. Narain, Ph.D., President & CEO, BPGbio, Inc. “Truly understanding the underlying biology that governs a disease process is the foundation to creating best in class therapeutics and diagnostics, NAi has been the cornerstone of our innovation and guided us to biology-based data-driven solutions for patients and families.”
The NAi Interrogative Biology Platform consists of an industry leading 100,000 sample, clinically annotated biobank, purpose-built Bayesian AI software, and unrivalled computing capability provided by the Oak Ridge National Laboratory (ORNL) Frontier Supercomputer, the fastest in the world. These unique components make NAi the only fully integrated high-performance computing (HPC) platform in the biopharmaceutical industry for AI-driven target nomination, discovery, and molecule design. The NAi Platform is available for commercial partnering for broad scale development, repurposing of drugs, identification of diagnostic biomarkers, and health analytics, and has been used by leading government, industry and academic partners including the United States Department of Defense (DoD), Sanofi, AstraZeneca, and Harvard Medical School.
Uniting the best-in-class in biology and technology for hypothesis-free discovery, NAi has delivered more than 100 drug and diagnostics targets and candidates, including its lead franchise drug candidate, BPM31510 IV, currently in Phase 2b and Phase 2a trials for glioblastoma multiforme (GBM) and pancreatic cancer, respectively. BPGbio also has identified therapeutic assets now in late clinical stage for epidermolysis bullosa (EB), squamous cell carcinoma (SCC), chemo-induced alopecia (CIA), sarcopenia, and other drug targets and compounds being assessed for various solid and liquid tumors, and neurodegenerative diseases.
The AI-driven insights generated from the NAi platform also offer a vast array of diagnostic potential. This includes an novel biomarker underlying the pstateDx test for prostate cancer, and other tests for pancreatic cancer, Parkinson’s disease, liver disease, and breast cancer in development or already clinically validated.
“I’m very pleased to see BPGbio’s NAi platform winning this special award,” said Eric J. Nestler, M.D., Ph.D, advisory board member of BPGbio, and Nash Family Professor of Neuroscience at the Icahn School of Medicine at Mount Sinai in New York. “The BPGbio team has perfected the highly innovative NAi platform over the past 10 years through extensive partnerships with many world-renowned scientists and organizations and NAi’s robust pipeline output is proof that integrating comprehensive biology and cutting-edge AI technology is the way to accelerate drug discovery.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today. This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world.
“By utilizing biology-first AI, BPGbio has demonstrated a bold, fundamental approach to drug discovery. BPGbio, our ‘Therapeutics Platform of the Year’ winner, is proving the value of AI in drug discovery for the future of medicine,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Instead of a traditional hypothesis-based approach, BPGbio is redefining how patient biology can be modeled by combining unbiased AI, biobank information and wet lab data for faster, cheaper, and more effective therapeutics development.”
About BPGbio, Inc.
BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the world’s largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way we understand aging, human performance, and diagnose and treat disease. For more information, visit bpgbio.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughawards.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
